REiNS is an international effort to develop new standardized response criteria for determining treatment response in patients with NF1, NF2, and schwannomatosis. Response criteria will continue to be modified as we gain experience in clinical trials for NF. We hope these criteria will be incorporated into future clinical trials and will improve our ability to determine and compare treatment efficacy.
History & Organization
The REiNS Collaboration was established in 2011 at the Children’s Tumor Foundation annual NF Conference to achieve consensus within the NF community about future clinical trials and to accelerate the identification of agents which will benefit individuals with NF. Since its inception, the REiNS International Collaboration has played a key role in the creation and dissemination of outcome measures for clinical trials of neurofibromatosis and schwannomatosis.
The REiNS collaboration is organized around eight working groups that focus on the following topics: imaging of tumor response, functional outcomes, visual outcomes, patient-reported outcomes, neurocognitive outcomes, whole-body MRI, disease biomarkers, and cutaneous neurofibromas. Leaders of the eight working groups were identified based on their expertise. Membership in each working group is open to any interested party and representatives from patient advocacy groups and funding agencies have been invited to participate in the effort. Each REiNS group establishes a meeting schedule; the majority of meetings are held by teleconference. In-person meetings of the entire group are held twice per year to coordinate efforts among the working groups and to achieve consensus within the larger group for recommendations.